Opinion of the Transparency Council – the active substance arsenic trioxide
At its meeting on 5 September 2022 the Transparency Council adopted opinion No.136/2022 on the inclusion in the reimbursement procedure of medicines containing the active substance arsenic trioxide for the indications for use or posology or route of administration other than those specified in the Summary of Product Characteristics.